Stryker's Q2 rebound confirms operational strength, but rich valuation remains a key concern

What happened

Stryker's Q2 2026 results show a strong rebound from the prior quarter's cybersecurity disruption, with sales rising 9.4% year-over-year to approximately $6.6 billion and organic growth near 9%. Adjusted EPS surged 18% to $3.69, and operating margin expanded 170 basis points to 27.4%, indicating robust profitability restoration. Despite this operational strength, the stock still trades at around 46 times trailing earnings and 30 times EV/EBITDA, a significant premium to the DCF-derived intrinsic value near $124 per share. The recovery validates the company's resilience but does not resolve the fundamental valuation overhang that underpinned the prior 'POTENTIAL SELL' judgment. Investors should recognize that while this quarter's performance is encouraging, it does little to bridge the wide gap between price and intrinsic value.

Implication

The solid Q2 results reduce near-term operational risk, yet the valuation remains detached from underlying fundamentals, with the stock trading far above conservative intrinsic value estimates. Sustained double-digit growth and margin expansion would be required to begin justifying the current multiple, and even then, the margin of safety is thin. Investors should monitor whether the cybersecurity recovery translates into sustained momentum in robotics and vascular segments, as those are key drivers of long-term value. Unless the stock undergoes a significant de-rating or growth accelerates meaningfully, the risk of multiple compression outweighs the upside. For value-oriented investors, this latest report supports trimming rather than adding positions.

Thesis delta

The Q2 recovery and margin expansion do not materially alter the investment thesis; the stock remains overvalued relative to its DCF-based intrinsic value. The operational rebound removes a near-term tail risk but does not address the persistent valuation gap that drove the 'POTENTIAL SELL' judgment. Consequently, no shift in stance is warranted at this time.